1. Home
  2. OBAI vs RVPH Comparison

OBAI vs RVPH Comparison

Compare OBAI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OBAI

TG-17 Inc. Common Stock

N/A

Current Price

$1.43

Market Cap

25.2M

ML Signal

N/A

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.83

Market Cap

29.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OBAI
RVPH
Founded
2017
2006
Country
United States
United States
Employees
N/A
14
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.2M
29.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OBAI
RVPH
Price
$1.43
$0.83
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$66.67
AVG Volume (30 Days)
543.4K
2.5M
Earning Date
05-26-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.17
52 Week High
$19.95
$3.11

Technical Indicators

Market Signals
Indicator
OBAI
RVPH
Relative Strength Index (RSI) 9.26 44.64
Support Level N/A $0.32
Resistance Level $2.15 N/A
Average True Range (ATR) 0.21 0.25
MACD 0.41 -0.17
Stochastic Oscillator 11.76 21.90

Price Performance

Historical Comparison
OBAI
RVPH

About OBAI TG-17 Inc. Common Stock

Our Bond Inc is a personal security service through its AI-powered Preventive Personal Security platform. It is trusted by corporations, cities, and universities, and has already supported more than 1.4 million security service requests, including over 10,000 emergencies and life-saving interventions.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: